In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ovid Therapeutics, Inc.

http://www.ovidrx.com/

Latest From Ovid Therapeutics, Inc.

Digital Health Roundup, July 2021: Exec Chat With DTA, Start-Ups Grab New Funds, Agency Nods

In this roundup feature focusing on the developments in digital health, we highlight the key news and announcements from July.

Digital Health Artificial Intelligence

Handheld Ultrasound Developer Exo Raised $220M In Series C

As Exo awaits FDA clearance for its handheld ultrasound device, it will use the new funding for planned commercialization. Exo has raised more than $320m to date. 

Financing Diagnostic Imaging

Takeda Highlights Rare Neurological Disorder Programs In Wave 1

Seeing significant unmet medical needs and insufficiently met needs in narcolepsy and rare types of epilepsy, Takeda has shifted its neuroscience focus.

Neurology Rare Diseases

Takeda Takes Back Dravet, Lennox-Gastaut Candidate From Ovid

Revising the two companies’ 2017 epilepsy collaboration, Takeda will take over Phase III development and commercialization of soticlestat. Ovid gets $196m up front, and it can shift focus.

Deals Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register